Palonosetron Prevents Highly Emetogenic Chemotherapy-induced Nausea and Vomiting in Oral Cancer Patients

ORAL CANCER STUDY GROUP OF CHUGOKU-SHIKOKU

Research output: Contribution to journalArticle

Abstract

BACKGROUND/AIM: To evaluate the efficacy of palonosetron in preventing acute and delayed nausea and vomiting in patients receiving highly emetogenic chemotherapy (HEC) in oral cancer patients.

PATIENTS AND METHODS: Oral cancer patients receiving HEC were enrolled; among the 40 patients, 87 courses of chemotherapy were administered. On day 1, 0.75 mg palonosetron was intravenously administrated just before chemotherapy.

RESULTS: The primary endpoint was the proportion of patients with a complete response (CR) and the secondary endpoint was the proportion of patients with complete control (CC) during the acute and delayed phase. During the acute phase, 86 of 87 courses (98.9%) had CR and 84 of 87 courses (96.6%) had CC. During the delayed phase, 84 of 87 courses (96.6%) had CR and 70 of 87 courses (80.5%) had CC.

CONCLUSION: Palonosetron is effective at preventing HEC-induced chemotherapy-induced nausea and vomiting (CINV) in oral cancer chemotherapeutic regimens in the acute and delayed phases.

Original languageEnglish
Pages (from-to)6977-6981
Number of pages5
JournalAnticancer Research
Volume37
Issue number12
Publication statusPublished - Dec 1 2017
Externally publishedYes

Fingerprint

Mouth Neoplasms
Nausea
Vomiting
Drug Therapy
palonosetron

Keywords

  • antiemetic therapy
  • Chemotherapy
  • nausea
  • oral cancer
  • palonosetron
  • vomiting

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Palonosetron Prevents Highly Emetogenic Chemotherapy-induced Nausea and Vomiting in Oral Cancer Patients. / ORAL CANCER STUDY GROUP OF CHUGOKU-SHIKOKU.

In: Anticancer Research, Vol. 37, No. 12, 01.12.2017, p. 6977-6981.

Research output: Contribution to journalArticle

ORAL CANCER STUDY GROUP OF CHUGOKU-SHIKOKU 2017, 'Palonosetron Prevents Highly Emetogenic Chemotherapy-induced Nausea and Vomiting in Oral Cancer Patients', Anticancer Research, vol. 37, no. 12, pp. 6977-6981.
ORAL CANCER STUDY GROUP OF CHUGOKU-SHIKOKU. / Palonosetron Prevents Highly Emetogenic Chemotherapy-induced Nausea and Vomiting in Oral Cancer Patients. In: Anticancer Research. 2017 ; Vol. 37, No. 12. pp. 6977-6981.
@article{b1409194ab0d4a5db6116a24e1c930dd,
title = "Palonosetron Prevents Highly Emetogenic Chemotherapy-induced Nausea and Vomiting in Oral Cancer Patients",
abstract = "BACKGROUND/AIM: To evaluate the efficacy of palonosetron in preventing acute and delayed nausea and vomiting in patients receiving highly emetogenic chemotherapy (HEC) in oral cancer patients.PATIENTS AND METHODS: Oral cancer patients receiving HEC were enrolled; among the 40 patients, 87 courses of chemotherapy were administered. On day 1, 0.75 mg palonosetron was intravenously administrated just before chemotherapy.RESULTS: The primary endpoint was the proportion of patients with a complete response (CR) and the secondary endpoint was the proportion of patients with complete control (CC) during the acute and delayed phase. During the acute phase, 86 of 87 courses (98.9{\%}) had CR and 84 of 87 courses (96.6{\%}) had CC. During the delayed phase, 84 of 87 courses (96.6{\%}) had CR and 70 of 87 courses (80.5{\%}) had CC.CONCLUSION: Palonosetron is effective at preventing HEC-induced chemotherapy-induced nausea and vomiting (CINV) in oral cancer chemotherapeutic regimens in the acute and delayed phases.",
keywords = "antiemetic therapy, Chemotherapy, nausea, oral cancer, palonosetron, vomiting",
author = "{ORAL CANCER STUDY GROUP OF CHUGOKU-SHIKOKU} and Shinya Sento and Naoya Kitamura and Tetsuya Yamamoto and Koichi Nakashiro and Hiroyuki Hamakawa and Soichiro Ibaragi and Akira Sasaki and Natsumi Takamaru and Yoji Miyamoto and Isamu Kodani and Kazuo Ryoke and Katsuaki Mishima and Yoshiya Ueyama",
year = "2017",
month = "12",
day = "1",
language = "English",
volume = "37",
pages = "6977--6981",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "12",

}

TY - JOUR

T1 - Palonosetron Prevents Highly Emetogenic Chemotherapy-induced Nausea and Vomiting in Oral Cancer Patients

AU - ORAL CANCER STUDY GROUP OF CHUGOKU-SHIKOKU

AU - Sento, Shinya

AU - Kitamura, Naoya

AU - Yamamoto, Tetsuya

AU - Nakashiro, Koichi

AU - Hamakawa, Hiroyuki

AU - Ibaragi, Soichiro

AU - Sasaki, Akira

AU - Takamaru, Natsumi

AU - Miyamoto, Yoji

AU - Kodani, Isamu

AU - Ryoke, Kazuo

AU - Mishima, Katsuaki

AU - Ueyama, Yoshiya

PY - 2017/12/1

Y1 - 2017/12/1

N2 - BACKGROUND/AIM: To evaluate the efficacy of palonosetron in preventing acute and delayed nausea and vomiting in patients receiving highly emetogenic chemotherapy (HEC) in oral cancer patients.PATIENTS AND METHODS: Oral cancer patients receiving HEC were enrolled; among the 40 patients, 87 courses of chemotherapy were administered. On day 1, 0.75 mg palonosetron was intravenously administrated just before chemotherapy.RESULTS: The primary endpoint was the proportion of patients with a complete response (CR) and the secondary endpoint was the proportion of patients with complete control (CC) during the acute and delayed phase. During the acute phase, 86 of 87 courses (98.9%) had CR and 84 of 87 courses (96.6%) had CC. During the delayed phase, 84 of 87 courses (96.6%) had CR and 70 of 87 courses (80.5%) had CC.CONCLUSION: Palonosetron is effective at preventing HEC-induced chemotherapy-induced nausea and vomiting (CINV) in oral cancer chemotherapeutic regimens in the acute and delayed phases.

AB - BACKGROUND/AIM: To evaluate the efficacy of palonosetron in preventing acute and delayed nausea and vomiting in patients receiving highly emetogenic chemotherapy (HEC) in oral cancer patients.PATIENTS AND METHODS: Oral cancer patients receiving HEC were enrolled; among the 40 patients, 87 courses of chemotherapy were administered. On day 1, 0.75 mg palonosetron was intravenously administrated just before chemotherapy.RESULTS: The primary endpoint was the proportion of patients with a complete response (CR) and the secondary endpoint was the proportion of patients with complete control (CC) during the acute and delayed phase. During the acute phase, 86 of 87 courses (98.9%) had CR and 84 of 87 courses (96.6%) had CC. During the delayed phase, 84 of 87 courses (96.6%) had CR and 70 of 87 courses (80.5%) had CC.CONCLUSION: Palonosetron is effective at preventing HEC-induced chemotherapy-induced nausea and vomiting (CINV) in oral cancer chemotherapeutic regimens in the acute and delayed phases.

KW - antiemetic therapy

KW - Chemotherapy

KW - nausea

KW - oral cancer

KW - palonosetron

KW - vomiting

UR - http://www.scopus.com/inward/record.url?scp=85038130164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038130164&partnerID=8YFLogxK

M3 - Article

C2 - 29187483

AN - SCOPUS:85038130164

VL - 37

SP - 6977

EP - 6981

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 12

ER -